Five major randomized controlled trials show that lowering hemoglobin A1C (a primary diabetes treatment target) does not improve morbidity or mortality outcomes, including the UK PDS, ROSIE trial, and ACCORD trial, indicating that A1C reduction is not a valid surrogate for metabolic improvement
factualpending
Speaker
Robert LustigEvidence Quote
“five studies that show that lowering A1C didn't help...mortality rate was actually higher with the talbutamide...intensive therapy worse statistically worse and cvd death statistically worse”
Source
The Subcellular Processes That Belie All Chronic Disease. The Hateful (or Grateful) Eight #lustig— Emery PharmaCreated: 8/10/2026, 10:44:48 PM
My Notes
Loading notes...